Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Mise à jour : Il y a 4 ans
Référence : NCT00732940

Femme et Homme

Extrait

The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.


Critère d'inclusion

  • Systemic Lupus Erythematosus

Liens